

Life Science Caucus Meeting

July 21, 2021

7:30am

Co-chairs:

Senators Newton and Woodard

Representatives White and Reives

Meeting will begin shortly



Agenda

- Welcoming Remarks by Chairs
 - Senators Paul Newton and Mike Woodard
 - Representatives Donna White and Robert Reives
- Introduction of Speakers
 - Laura Gunter, President, NCBIO
- Presentation – G1 Therapeutics
 - Jack Bailey, CEO and President
- Presentation – United Therapeutics
 - Gil Golden, MD, PhD, Executive VP and Chief Medical Officer
- Presentation – ThermoFisher
 - Alex Graham, VP, Commercial Operations
- Q&A/Discussion
- Adjourn



Jack Bailey serves as CEO and President of G1 Therapeutics, a commercial-stage oncology company based in RTP, NC. The company's lead asset Cosela is an FDA-designated Breakthrough Therapy for the treatment of chemotherapy-induced myelosuppression. G1 is developing the product for a wide array of different tumor types to provide either myeloprotection and/or anti-tumor efficacy. Prior to becoming CEO of G1 Therapeutics, Bailey was President of GSK-U.S., leading the largest part of the global corporation to five straight years of over-Plan performance and growth.



Prior to GSK, Bailey had a successful 18-year career at Eli Lilly & Company where he finished as Senior Vice-President in charge of the Oncology, Cardiovascular and Managed Markets divisions.

Bailey received his undergraduate degree in Biology from Hobart College in Geneva, New York, followed by his Master's in Business Administration from the Kenan-Flagler School of Business at the University of North Carolina–Chapel Hill.

Bailey's current industry-related roles include Board member with EMERGO, an RTP-based biotechnology company, and Board member of the UNC Health System. Previous Board roles include past member of the T.H. Chan School of Public Health Advisory Board at Harvard University, past Board member of PhRMA, the industry trade association, past member of the NC Chamber of Commerce where he was also the Chair, and past Board member at the North Carolina Biotechnology Center.



Dr. Gil Golden, Executive VP and Chief Medical Officer, has demonstrated leadership within the biopharma industry for over two decades, overseeing numerous functions, including: product development, research and educational grants, medical education and information, pharmacovigilance, regulatory affairs, corporate project management, business development, and corporate compliance, among others. Throughout this time, his work in the US and globally, has maintained a strong focus on preclinical through phase IV drug, device, and biologics development.

Much of this product development work was executed through government, foundation, university, and industry partnerships designed to address unmet medical needs and/or to improve a product's efficacy or safety profile, while expanding access of medicine to expanded patient populations. At the present time, he contributes strategically to all phases of product development and has oversight of Company support of approximately three dozen innovative investigator sponsored studies.

Prior to joining United Therapeutics, Dr. Golden has held executive positions with Guilford Pharmaceuticals, Pharmion Corporation, and Azur Pharma. Dr. Golden obtained his graduate degree in neuroendocrinology from the University of Pittsburgh and his pre- and post-graduate medical training from the Medical College of Pennsylvania.

He has authored numerous peer-reviewed papers on medical education and various aspects of drug development, spanning the molecular level to global multi-center randomized clinical trials.



The world leader in serving science

Alex Graham, is Vice President of Commercial Operations with ThermoFisher Scientific. He is responsible for leading a team that maximizes the productivity and effectiveness of the Sales and Marketing organization. Includes planning and forecasting, reporting and analysis, process optimization, system selection and configuration, target setting, sales compensation design and implementation, sales training and inside sales. He's been with ThermoFisher since 2012 and had previous sales and financial operations experience. He holds a BA in Psychology from Lyndon State College and an MBA, Finance, from Queens University of Charlotte.





NOW APPROVED
COSELA™
trilaciclib for injection
300 mg

Optimizing Chemotherapy, Advancing Survival

Life Science Caucus Meeting
July 21, 2021



Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, those relating to the therapeutic potential of COSELA™ (trilaciclib), rintodestrant and lerociclib, COSELA's possibility to improve patient outcomes across multiple indications, rintodestrant's potential to be best-in-class oral SERD, our reliance on partners to develop and commercial licensed products, and the impact of pandemics such as COVID-19 (coronavirus), and are based on the company's expectations and assumptions as of the date of this presentation. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause the company's actual results to differ from those expressed or implied in the forward-looking statements in this presentation are discussed in the company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, the company's ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; the company's initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a development-stage company; and market conditions. Rintodestrant and lerociclib are not approved by the FDA. The safety or effectiveness of rintodestrant and lerociclib have not been established by the FDA. Except as required by law, the company assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

G1Therapeutics™ and G1Therapeutics logo and COSELA™ and COSELA logo are trademarks of G1 Therapeutics, Inc.
©2021 G1 Therapeutics, Inc.

G1 Therapeutics, Inc.

From Idea to Discovery to Development to Commercialization


- **May 19, 2008 - Founded – Certificate of Incorporation filed in DE**
- **October 25, 2010 – Filed First U.S. Patent for Trilaciclib**
- **May 16, 2017 – Initial Public Offering**
- **2018 – Reported Phase II Data for Trilaciclib in SCLC**
- **August 14, 2020 - FDA Accepted NDA filing for Trilaciclib in SCLC**
- **February 12, 2021- FDA Approved Trilaciclib (brand name COSELA) for use in SCLC**

**G1 inspired by fundamental science out of UNC-CH lab run by Dr. Ned Sharpless.
Success as a result of private sector, university & government relationship**

G1 Therapeutics


COSELA (trilaciclib) is a Cornerstone Therapy

COSELA[™]
trilaciclib for injection
300 mg



Focused on the development and commercialization of COSELA

Aggressively Pursuing Development in Common Tumor Types



**G1 has initiated sponsored studies
in many of the most common and deadly tumor types**

G1 Possible Because NC Business-friendly Environment

- **Highly educated labor pool (UNC/Duke/NC State/Wake)**
 - Almost 50% of the population has a bachelor degree and 20% has a doctorate
- **A competitive tax & regulatory environment**
- **Ability to attract and retain high quality people**
 - #2 “Best Place to Live” – 2021 U.S. News & World Report
 - Affordable real estate and cost of living
- **Home of Research Triangle Park & growing life science and I.T. “ecosystems”**

**North Carolina has established an excellent business environment
& we must continue to keep North Carolina competitive**

Two Suggestions:

1) Improve the Administrative / Regulatory Environment

- Revise the state licensing statutes/process for biopharma companies to allow them to obtain a NC state license that is conditioned on FDA approval (follow other states)

2) Repeal the Franchise Tax for Pre-Revenue Companies

- NC is among a limited number of states that continue to have a Franchise Tax

Continue to make North Carolina competitive for job-creating small businesses



UNITED THERAPEUTICS CORPORATION


July 2021



Founded to Save a Daughter's Life

Dedicated to finding a cure for PAH and other rare lung diseases


LIVES IMPACTED TODAY






INVESTING IN OUR EMPLOYEE TALENT

EMPLOYEES
950+ total



RANGE OF JOBS IN NC



AVERAGE NC COMPENSATION

\$190k
Minimum living wage of **\$75k**¹

1. \$62,500 minimum cash compensation with a 20% cash bonus target. Excludes additional stock grants available to all employees

AMENITIES FOR EMPLOYEES IN NC





CONTINUED COMMITMENT TO ESG

PATIENTS


LUNG BIOTECHNOLOGY PBC⁽¹⁾: Created to address the national shortage of lungs and transplantable organs



FIRST PBC⁽¹⁾ FOR A PUBLIC BIOTECH


PEOPLE

Commitment to Diversity & Inclusion



PLANET

11 solar arrays



20% of annual electricity consumption

The **Unisphere**: Largest **site net-zero energy** office building

PRINCIPLES

- 1 WE ARE PASSIONATE FOR PATIENTS
- 2 WE DON'T PAY TO PLAY
- 3 WE RESPECT PRIVACY
- 4 WE COMMUNICATE ETHICALLY & HONESTLY
- 5 WE DO THE RIGHT THING

(1) PBC = Public Benefit Corporation



SEEKING CREATIVE SOLUTIONS TO PRESSING HUMAN NEEDS




TRANSPLANT NEED

~40k US transplants per year

~109k US transplant waiting list

900k US deaths per year from organ impairment

EVLP




XENO-TRANSPLANTATION



REGEN



3DAP





RECENT AND FUTURE EXPANSION IN NC

REGEN MANUFACTURING



OPERATIONAL

LIGHTYEAR



NET CARBON ZERO

eVTOL



SOLAR RECHARGING



**United
Therapeutics**

C O R P O R A T I O N

Life Science Caucus Meeting


Pharma Services Group

Alex Graham

VP of Commercial Operations

July 21, 2021

 The world leader in serving science



Introduction



VP, Group Commercial Operations, PSG



VP, Sales & Marketing Operations




Director, Sales Operations
Thomson Reuters
2005 – Sep 2012 · 7 yrs



Global Director, Financial Planning & Analysis
Timberland
2000 – 2005 · 5 yrs



Director, Sales Administration
Baker & Taylor
1997 – 2000 · 3 yrs



Manager, Financial Planning & Analysis
Maersk Line
1995 – 1997 : 2 yrs



Thermo Fisher & North Carolina



Asheville, NC
28 Schenck Parkway
Building #400
Asheville, NC 28803



Commercial Manufacturing, Formulation & Development,
Softgels

High Point, NC
4125 Premier Drive
High Point, NC 27265

Phone: +1 336 812 8700

- Site Information
- Site Capabilities Fact Sheet
- Visiting High Point



Corporate, Corporate Office

Durham, NC
4815 Emperor Boulevard
Durham, NC 27703-8470



Commercial Manufacturing, Formulation & Development,
Steriles

Greenville, NC
5900 Martin Luther King Jr. Highway
Greenville, NC 27834

Phone: +1 252 758 3436

- Site Information
- Site Capabilities Fact Sheet
- Visiting Greenville, NC

Thermo Fisher Invests in North Carolina



Gov. Cooper to tour Thermo Fisher facility in Asheville

THERMO FISHER ADDS 200 JOBS BECAUSE OF COVID-19 PANDEMIC

Governor Cooper will be touring the Asheville facility on Friday, July 2, at 2:45 p.m. and will make statements following his visit.

Thermo Fisher to help manufacture Moderna's COVID-19 vaccine

Katie Adams - Wednesday, June 2nd, 2021 [Print](#) | [Email](#)

[Share](#) [Tweet](#) [Share 0](#) [Listen](#)

Thermo Fisher signed an agreement to provide fill and finish manufacturing for "hundreds of millions of doses" of Moderna's COVID-19 vaccine, the drugmakers announced June 1.

Beginning in the third quarter of 2021, Thermo Fisher will produce Moderna's vaccine using its manufacturing plant in Greenville, N.C.

Thermo Fisher Scientific is expanding its site in Greenville for sterile drug product development and commercial manufacturing of critical medicines, therapies, and vaccines. As part of the approximately \$500 million investment, the global life science services company will create about 500 new jobs over next 12 to 24 months.

"We are excited by the news of Thermo Fisher's investment in their Greenville facility which further strengthens Greenville and Pitt County's legacy as a hub of pharmaceutical production," said Steve Weathers, president and CEO of the [Greenville – Eastern North Carolina \(ENC\) Alliance](#). "Our area has more than 2,000 people working in pharmaceutical manufacturing occupations which is a concentration 12 times higher than the United States."



The 1.5 million-square-foot Greenville site is a multi-purpose pharmaceutical manufacturing and packaging campus with a current workforce of more than 1,500 employees. The expansion will include a new standalone 130,000-square-foot facility with two live virus filling lines which will be operational in 2022.

Thermo Fisher Invests in North Carolina



ThermoFisher
SCIENTIFIC

PPD

Thermo Fisher Scientific to Acquire PPD, Inc.

Establishes Thermo Fisher as a Global Leader in Attractive, High Growth Clinical Research Services Industry

Transaction Highlights

\$17.4B

Total cash purchase price¹

PPD shareholders to receive \$47.50 per share in cash

Represents a premium of ~24% to unaffected closing price of PPD's common stock on the Nasdaq as of 4/13/21, or 32% to the 60-day VWAP inclusive of that date

PPD shareholders holding ~60% of issued and outstanding shares have approved transaction

PPD: A Leading Clinical Research Organization

\$4.7B

REVENUE²

15%

ADJ. OPERATING MARGIN

26,000+

EMPLOYEES

165

FACILITIES

NEARLY 50

COUNTRIES

REVENUE BY SEGMENT³

Clinical Development Services

Offers full-service clinical trial management

81%

19%

Laboratory Services

Offers highly specialized lab capability to support clinical trials

REVENUE BY GEOGRAPHY³

NORTH AMERICA

56%

EMEA

29%

APAC

11%

ROW

4%

24

Proprietary & Confidential | alex.graham@thermofisher.com

Thermo Fisher Partners with North Carolina



RESEARCH TRIANGLE PARK – “I really love my job,” says Diana De Leon, a 2020 graduate of North Pitt High School in Greenville, N.C. De Leon is a newly minted operator at Thermo Fisher Scientific, a contract manufacturer of pharmaceuticals in her hometown.

De Leon landed her job at Thermo Fisher Scientific in the summer of 2020 after graduating from high school and completing a specialized training program called the Pharma K12 Workforce Training Development Initiative. The program gives interested high school seniors in Pitt County an introduction to commercial drug manufacturing, so they are primed for entry-level production jobs. The students learn in a pilot-scale manufacturing environment at the Pharmaceutical Services Network at Pitt Community College.

BIOTECH CENTER INVOLVED

The training program was conceived by Mark Phillips, vice president of statewide operations and executive director of the Eastern Regional Office of the North Carolina Biotechnology Center. He proposed a sponsorship opportunity to Thermo Fisher Scientific in early 2019 as a pilot program for interested seniors from North Pitt High School.

“The success of this program would not be possible without the continued sponsorship and support from Thermo Fisher Scientific, as well as the support from Pitt County Schools’ Career – Technical Education Department and Pitt Community College’s Pharmaceutical Services Network”

Thermo Fisher Partners with North Carolina

As the world leader in serving science, Thermo Fisher has alignment with the scientific community's findings on human contribution to climate change. **We are committed to reducing our carbon footprint** and have set a target to reduce our scope 1 and 2 emissions **by 30%** (over 2018 levels) by the end of 2030.

Life Science Caucus Meeting

July 21, 2021

Questions and Wrap Up



Life Science Caucus Meeting

July 21, 2021

8:30am

Co-chairs:

Senators Newton and Woodard

Representatives White and Reives

Meeting adjourned

